Damora Therapeutics Inc.

2 months ago · globenewswire.com

-- DMR-001 is a highly potent, long-acting antibody therapy targeting Type 1 and non-Type 1 mutant calreticulin (mutCALR), designed for convenient once-monthly subcutaneous dosing -- -- In preclinical studies, DMR-001 demonstrated up to 30-fold greater potency and an approximately five-fold longer half-life than a reference anti-mutCALR antibody, supporting its best-in-class potential -- WALTHAM, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced the initiation of the global Phase 1/1b CLARITY-101 clinical trial of DMR-001, an investigational monoclonal antibody therapy designed to selectively target mutant calreticulin (mutCALR), in patients with mutCALR-driven essential thrombocythemia (ET) and myelofibrosis (MF), based on receipt of health authority approval.

2 months ago · globenewswire.com

BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (Damora or the Company) (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced the completion of the redomestication of the Company from the State of Delaware to the Cayman Islands, effective on July 16, 2026. Each outstanding share of the Delaware Company's common stock automatically converted into one ordinary share, par value $0.00001 per share, of the Company, and each outstanding share of any series of the Delaware Company's preferred stock automatically converted into one outstanding share of the corresponding series of the preferred shares of the Company. The redomestication was previously approved by the Company's board of directors and subsequently approved by the stockholders of the Company at a Special Meeting of Stockholders held on February 9, 2026.

4 months ago · seekingalpha.com

Damora Therapeutics is focused on mutant-CALR blood diseases, with DMR-001 as its lead asset. They have approximately $562.3 million in cash, and management believes this gives them enough runway into 2029. DMRA's lead asset has potential competitors in more advanced R&D stages. This helps validate the asset class as a whole, but DMRA still needs more data of its own.

6 months ago · zacks.com

The average of price targets set by Wall Street analysts indicates a potential upside of 73.1% in DAMORA THERAPEU (DMRA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.